ArticleOncoTargets and therapy2019

miR-596 suppresses the expression of Survivin and enhances the sensitivity of osteosarcoma cells to the molecular targeting agent anlotinib.

Leisheng Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.